Advertisement

Immunohistochemistry as confirmatory test for current Helicobacter pylori infection in patients treated with proton pump inhibitors

  • Anca Negovan
    Affiliations
    University of Medicine and Pharmacy, Clinical Science-Internal Medicine, Tirgu Mureș, Gheorghe Marinescu 38, 540139, Romania
    Search for articles by this author
  • Mihaela Iancu
    Correspondence
    Corresponding author.
    Affiliations
    University of Medicine and Pharmacy “Iuliu Hațieganu”, Department of Medical Informatics and Biostatistics, Louis Pasteur St, no. 6, 400349 Cluj-Napoca, Romania
    Search for articles by this author
  • Simona Mocan
    Affiliations
    Emergency County Hospital, Pathological Department, Tirgu Mures, Gheorghe Marinescu 50, 540136 Mures, Romania
    Search for articles by this author
  • Claudia Banescu
    Affiliations
    University of Medicine and Pharmacy, Department of Morphological Science, Genetic, Tirgu Mureș, Gheorghe Marinescu 38, 540139, Romania

    Genetics Laboratory, Center for Advanced Medical and Pharmaceutical Research, University of Medicine and Pharmacy, Tirgu Mureș, Gheorghe Marinescu 38, 540139 Mures, Romania
    Search for articles by this author
Published:December 01, 2017DOI:https://doi.org/10.1016/j.ejim.2017.11.013
      We would like to thank Dr. Davide Giuseppe Ribaldone and colleagues for their interest in our article “The contribution of clinical and pathological predisposing factors to severe gastro-duodenal lesions in patients with long-term low-dose aspirin and proton pump inhibitor therapy” [
      • Negovan A.
      • Iancu M.
      • Moldovan V.
      • et al.
      The contribution of clinical and pathological predisposing factors to severe gastro-duodenal lesions in patients with long-term low-dose aspirin and proton pump inhibitor therapy.
      ].They raised the problem of possible false negative diagnosis of Helicobacter pylori (H. pylori) infection using biopsy in patients with ongoing treatment with proton pump inhibitors (PPI) and offer us the opportunity to clarify some methodological aspects. They also discussed the possibility of cessation of PPI before endoscopy and the evaluation of antibodies to H. pylori in serum as a confirmatory test of infection, which allow us to comment certain local aspects of this issue.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Negovan A.
        • Iancu M.
        • Moldovan V.
        • et al.
        The contribution of clinical and pathological predisposing factors to severe gastro-duodenal lesions in patients with long-term low-dose aspirin and proton pump inhibitor therapy.
        Eur J Intern Med. 2017; 44: 62-66
        • Bhatt D.L.
        • Scheiman J.
        • Abraham N.S.
        • et al.
        American College of Cardiology Foundation Task Force on clinical expert consensus documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents.
        Circulation. 2008; 118 (28): 1894-1909
        • Malfertheiner P.
        • Megraud F.
        • O'Morain C.A.
        • on behalf of the European Helicobacter and Microbiota Study Group and Consensus panel
        • et al.
        Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report.
        Gut. 2017; 66: 6-30
        • Rugge M.
        • Pennelli G.
        • Pilozzi E.
        • et al.
        Gastritis: the histology report.
        Dig Liver Dis. 2011; 43: S373-84
        • Hunt R.H.
        • Camilleri M.
        • Crowe S.E.
        • et al.
        The stomach in health and disease.
        Gut. 2015; 64: 1650-1668
        • Stolte M.
        • Meining A.
        • Schmitz
        • et al.
        Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.
        Aliment Pharmacol Ther. 1998; 12: 247-253
        • Lundell L.
        • Vieth M.
        • Gibson F.
        • Nagy P.
        • Kahrila J.
        Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.
        Aliment Pharmacol Ther. 2015; 42: 649-663
        • Malfertheiner P.
        • Kandulski A.
        • Venerito M.
        Proton-pump inhibitors: understanding the complications and risks.
        Nat Rev Gastroenterol Hepatol. Sep 20, 2017; https://doi.org/10.1038/nrgastro.2017.117